Likewise, the correlation between KRAS and glycolysis was further reinforced by immunostaining analysis in CRC tissues, which revealed that tumors with mutant KRAS had a higher expression of tumor glycolytic enzymes, including GLUT1, GLUT3, and HK2, than the tumors with wild-type KRAS (Supplementary Fig. 2n, o). The gene discussed is KRAS; the disease is neoplasm.